Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00348946 · ClinicalTrials.gov registry record · Phase 2
Androgen Effect on Klinefelter Syndrome Motor Outcome
A Phase 2 study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT00348946: Completed Phase 2 study, sponsored by Thomas Jefferson University.
NCT00348946 is a Phase 2 study that has completed, run by Thomas Jefferson University. The registered enrollment target is 93 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00348946, a Phase 2 study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of low-dose androgen on the motor and cognitive development of boys with Klinefelter syndrome.
Primary Outcome
Outcome measures were tested using the following assessments: Bruininks-Osertesky Test of Motor Proficiency (BOT) subscales of (1) Visual Motor Control, (2) Upper limb Speed, and (3) Strength, Physical and Neurological Evaluation for Soft Signs (PANESS), and Hand Strength Dynamometer. BOT assess the child's motor development and includes standard scores (mean=100, SD=15) and subtest scores and is normed for sex and age (4-14.5 years). PANESS assesses the time required to press thumb to 4 fingers
Interventions
- OTHER placebo
- DRUG androgen oxandrolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2006-07 |
| Est. Completion | 2017-11-30 |
| Phase | Phase 2 |
What the finished NCT00348946 record still lists
NCT00348946 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00348946 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00348946 about?
NCT00348946 is a clinical study titled "Androgen Effect on Klinefelter Syndrome Motor Outcome". The purpose of this study is to evaluate the effects of low-dose androgen on the motor and cognitive development of boys with Klinefelter syndrome.
What is the current status of trial NCT00348946?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2006-07. Estimated completion is 2017-11-30.
What interventions are being tested in trial NCT00348946?
The interventions under investigation include: placebo (OTHER), androgen oxandrolone (DRUG).
Who is sponsoring clinical trial NCT00348946?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00348946's enrollment target sits among peer trials
93 766th of 2000 higher than 1,234 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia